Objective-To determine whether increased 12/15-lipoxygenase (12/15LO) expression in vivo enhances neointimal formation in response to injury. Methods and Results-12/15LO expression in the vessel wall is increased in animal models of metabolic syndrome and diabetes mellitus. Increased expression of 12/15LO enhances cultured vascular smooth muscle cell (VSMC) proliferation, an effect mediated by the helix-loop-helix factor inhibitor of differentiation 3 (Id3). Carotid endothelial denudation was performed on apolipoprotein (Apo) E Ϫ/Ϫ , ApoE Ϫ/Ϫ /12/15LO Ϫ/Ϫ , C57BL/6, and 12/15LO-overexpressing transgenic mice. ApoE Ϫ/Ϫ /12/15LO Ϫ/Ϫ mice had attenuated and 12/15LO-overexpressing transgenic mice had enhanced neointimal formation compared with control mice. 12/15LO-overexpressing transgenic mice had greater postinjury carotid Id3 and Ki-67 expression, cell number, and fibronectin deposition compared with C57BL/6 mice. Loss of 12/15LO attenuated proliferation of cultured ApoE Ϫ/Ϫ VSMCs, whereas 12/15LO overexpression induced VSMC proliferation. Loss of Id3 enhanced immunoglobulin trascription factor (ITF)-2b binding to and activation of the p21 cip1 promoter and abrogated 12/15LO-induced VSMC proliferation. Conclusion-To our knowledge, these data are the first demonstration that increased expression of 12/15LO in the vessel wall enhances Id3-dependent cell proliferation, fibronectin deposition, and neointimal formation in response to injury. Results identify p21 cip1 as a potential target of the 12/15LO-Id3 pathway and suggest that modulation of this pathway may have therapeutic implications for targeting the increased risk of restenosis in patients with diabetes. (Arterioscler Thromb Vasc Biol. 2011;31:110-116.)
I ndividuals with type 2 diabetes mellitus have increased rates of restenosis after vascular interventional procedures. 1, 2 Vascular smooth muscle cell (VSMC) proliferation and matrix production are key events in the process of neointimal formation (NIF) after percutaneous interventions. 3, 4 Identifying the molecular mechanisms that mediate acceleration of these processes may provide important insight into strategies to attenuate restenosis in high-risk populations, such as those with type 2 diabetes.
Previous studies have implicated 12/15-lipoxygenase (12/ 15LO) in the vascular response to injury. 12/15LO products of arachidonic acid, such as 12S-hydroxyeicosatetrenoic acid (HETE), 15S-HETE, and 13S-hydroperoxyoctadecadienoic acid (HPODE), are produced in VSMCs and have hypertrophic effects. 5, 6 In vitro, 12/15LO inhibition attenuates hypertrophic effects of angiotensin II in VSMCs, mitogenic effects of cytokines, and chemotactic effects of platelet-derived growth factor. 5, 7, 8 Compared with VSMCs from C57BL/6 (BL-6) mice, VSMCs from 12/15LO-overexpressing transgenic (12/15LO-tg) mice grow faster, and VSMCs from 12/15LO Ϫ/Ϫ mice grow slower and display decreased S-phase entry in culture. 9,10 12/15LO and its products are increased in the vascular wall of animal models of atherosclerosis and injury-induced restenosis. 11 Compared with uninjured carotids, 12/15LO expression is significantly increased in rat carotids on day 12 after injury. 12 Moreover, pharmacological or ribozyme-mediated inhibition of the 12/ 15LO gene in vascular injury models results in attenuated NIF 12, 13 ; yet, the effects of baseline elevations in 12/15LO on injury-induced NIF and the factors downstream of 12/15LO that mediate these effects in vivo are incompletely understood.
Many conditions that are implicated in accelerated vascular response to injury are associated with enhanced 12/15LO expression. In particular, there is evidence that activity and levels of 12/15LO are increased in those with diabetes. Patients with type 2 diabetes have increased levels of 12-HETE in the urine. 14 Treatment of cultured VSMCs with high levels of glucose increases the expression of 12-and 15-HETEs. 15 Furthermore, 12/15LO expression is increased in the vascular wall in a porcine model of diabetes. 11 Endothelial cells isolated from db/db diabetic mice have increased 12/ 15LO expression, whereas the db/db mice also have increased levels of 12S-and 15S-HETE in vivo. 16 The obese Zucker rat model of metabolic syndrome also displays increased carotid 12/15LO expression and NIF after balloon angioplasty relative to lean Zucker rats. 17 Similarly, other candidates implicated in vascular response to injury, including angiotensin II, growth factors (eg, platelet-derived growth factor), and inflammatory cytokines (eg, interleukin 1), are also known to be potent inducers of 12/15LO expression and activity in VSMCs. 11,18 -21 Inhibitor of differentiation 3 (Id3) is a helix-loop-helix (HLH) transcription factor that functions as an important regulator of cellular growth. 22 Id3 expression is induced in response to mitogen stimulation, and inhibition of Id3 blocks mitogen-induced proliferation. [23] [24] [25] Id3 expression in vivo is significantly increased on days 3 and 7 after vascular injury and returns to baseline by day 28. 26, 27 Previous studies have demonstrated that 12/15LO induces Id3 expression and enhances growth in cultured VSMCs. More importantly, overexpression of 12/15LO in culture increases growth in BL-6 VSMCs but not in Id3 Ϫ/Ϫ VSMCs. 10 The goal of the current study was to determine whether the effects of increased 12/15LO on Id3 expression and proliferation in VSMCs in culture occurred in vivo and if increased expression of 12/15LO at baseline increases NIF in response to injury.
Methods
The supplemental material provides full details of the methods (available online at http://atvb.ahajournals.org).
Real-time RT-PCR, 28 immunohistochemistry, 26 cell culture, 26 chromatin immunoprecipitation, 28 and promoter-reporter analysis 10 were performed as previously described.
Animals
Studies were performed in accordance with the institutional guidelines at the University of Virginia, Charlottesville. BL-6, apolipoprotein (Apo) E Ϫ/Ϫ , ApoE Ϫ/Ϫ /12/15LO Ϫ/Ϫ (DKO), 12/ 15LO-tg, and 12/15LO-tg/Id3 Ϫ/Ϫ mice were used for left common carotid artery (LCCA) wire injury experiments. In an attempt to minimize variation, bias, and the number of animals used, all wire injury in our study was performed by a single experienced individual (H.P.) blinded to the genotype of the mice.
Measurement of Histopathologic Features
LCCA sections were stained using the Russell-modified method of Movat. 29 Every injury section in all groups was reviewed by a panel of scientists experienced in vascular injury who were blinded to the genotypes of the injured mice. Any animal with visible disruption of the internal elastic lamina was excluded before unblinding. Thus, every section that is included in the analysis has an intact elastic lamina.
Statistical Analysis
Statistical analyses were performed using computer software (PRISM 4). The Mann-Whitney U test was used to compare continuous variables between groups, and PϽ0.05 was considered significant. ANOVA was performed to evaluate the differences between multiple groups on continuous variables. Data are shown as meanϮSD.
Results

Increased 12/15LO Expression Increases NIF in BL-6 Mice and 12/15LO Deficiency Attenuates NIF in ApoE ؊/؊ Mice
To evaluate whether the 12/15LO expression level at baseline influences NIF after vascular injury, 10-to 12-week-old male BL-6 (nϭ8), 12/15LO-tg (nϭ11), ApoE Ϫ/Ϫ (nϭ5), and DKO (nϭ9) mice were fed a Western diet for 1 week, after which they underwent LCCA endothelial denudation. We chose a 12/15LO knockout model on an ApoE Ϫ/Ϫ background to show the "loss of function" after loss of 12/15LO because, unlike ApoE Ϫ/Ϫ , BL-6 mice do not form a robust neointima in response to injury. Loss of 12/15LO was confirmed by PCR genotyping (Supplemental Figure I) . Twenty-eight days after wire injury, animals were euthanized and the LCCAs were harvested. Histomorphometric analysis revealed that 12/ 15LO-tg mice had a significantly greater NIF compared with BL-6 mice (3427Ϯ2017 versus 1469Ϯ2162 m 2 ; Pϭ0.023), as shown in Figure 1A and 1B. Also consistent with prior inhibitor studies, the ApoE Ϫ/Ϫ control mice developed a significant neointima in response to wire injury, whereas loss of 12/15LO resulted in a significant reduction in lesion size (81 824Ϯ14 151 versus 26 461Ϯ 26 529 m 2 ; Pϭ0.007), as shown in Figure 1C and 1D. There were no differences in glucose, cholesterol, or triglyceride levels between the groups (data not shown). 
Id3 Expression in Response to Injury Is Greater in LCCA of 12/15LO-tg Mice
Prior studies demonstrated that cultured VSMCs from 12/ 15LO-tg animals had greater expression of Id3 than VSMCs from BL-6 mice and that 12LO-induced VSMC proliferation was mediated by Id3. Moreover, Id3 expression is increased in response to vascular injury in vivo. 26, 27 To determine whether 12/15LO-tg mice have enhanced Id3 expression in response to injury compared with BL-6 mice, LCCAs were harvested at 7 and 14 days after injury and were analyzed for 12/15LO and Id3 mRNA expression levels. As expected, 12/15LO-tg mice had greater 12/15LO expression in LCCAs after injury compared with BL-6 mice (Figure 2A ). Consistent with prior in vitro data, mice with increased 12/15LO expression had an increased Id3 mRNA level in the vessel wall compared with BL-6 mice ( Figure 2B ).
12/15LO-tg Mice Have Enhanced Neointimal Cell Proliferation, an Effect Attenuated by Loss of Id3
Analysis of neointima 28 days after injury indicates that there are more cells in the neointima of 12/15LO-tg mice compared with BL-6 mice (supplemental Figure II) .
Ki-67 staining was performed 7 days after injury to evaluate for in vivo differences in proliferation postinjury in 12/15LO-tg versus BL-6 mice. Results demonstrate signifi-cantly more neointimal, but not medial, cell proliferation in 12/15LO-tg mice compared with BL-6 mice. Interestingly, cell proliferation was significantly attenuated in 12/15LO-tg mice null for Id3 compared with 12/15LO-tg mice ( Figure 3A and 3B).
12/15LO Enhances VSMC Proliferation in Culture, an Effect That Is Attenuated by Id3 Deficiency
We compared growth rates for matched passage (7-9) cultured VSMCs from BL-6, Id3 Ϫ/Ϫ , 12/15LO-tg, and 12/15LOtg/Id3 Ϫ/Ϫ mice by direct cell counting. Similarly, we compared the growth rate between VSMCs from ApoE Ϫ/Ϫ and DKO mice. Consistent with our in vivo data, 12/15LO-tg VSMCs had accelerated proliferation compared with the BL-6 and loss of Id3 in 12/15LO-tg VSMCs resulted in a significant reduction in their proliferation ( Figure 4A ). Moreover, VSMCs from DKO mice had attenuated proliferation compared with VSMCs from ApoE Ϫ/Ϫ mice ( Figure 4B ). Similar growth rates were observed using a fluorometric DNA assay (data not shown).
Loss of Id3 Enhances ITF-2b Binding to and Activation of the p21 cip1 Promoter
Id3 is a known growth factor-inducible gene that inhibits VSMC expression of the cyclin-dependent kinase inhibitor p21 cip1 . To explore a mechanism by which Id3 accelerates VSMC growth, we examined the effect of Id3 on the binding of HLH factor ITF-2b to the p21 cip1 promoter by chromatin immunoprecipitation. Interestingly, ITF-2b binding to p21 cip1 promoter was enhanced after loss of Id3 in 12/15LO-tg VSMCs ( Figure 5A ). In addition, by promoter-reporter assays, we demonstrated that ITF-2b expression potentiates p21 cip1 promoter activity ( Figure 5B ).
12/15LO-tg Mice Have More Neointimal Fibronectin Deposition Compared With BL-6 Mice
Reddy et al 6 previously demonstrated that 12S-HETE induces fibronectin promoter activity in VSMCs. To determine whether 12/15LO increases fibronectin production in vivo, potentially contributing to increased NIF in 12/15LO-tg mice, we performed immunostaining for fibronectin on 28-day postinjury LCCA sections (8 animals in each group). When compared with BL-6 mice, 12/15LO-tg mice had signifi- Figure 5 . Id3 deficiency enhances ITF-2b binding to p21 cip1 promoter, and ITF-2b binding increases p21 cip1 promoter activity. To explore a mechanism by which Id3 accelerates VSMC growth, we examined the effect of Id3 on the binding of HLH factor ITF-2b to the p21 cip1 promoter by chromatin immunoprecipitation (ChIP). VSMCs of 12/15LO-tg and 12/15LO-tg/Id3 Ϫ/Ϫ mice were cross-linked and precipitated with the indicated antibodies, and immunoprecipitated DNA fragments were quantified by real-time PCR and normalized to an internal ␤-galactosidase control for recovery. ChIP for RNA polymerase-II was used as positive control. A, Results are presented as fold increase in percentage recovery relative to IP with isotype control and are the average of triplicate PCR measurements from 4 independent ChIPs. In addition, we demonstrated that ITF-2b binding to p21 cip1 promoter enhances its transcription. BL-6 and Id3 Ϫ/Ϫ VSMCS were cotransfected with a pEF4 -ITF-2b expression vector and a pGL3 vector harboring 2.3-Kb human p21 cip1 promoter. Twenty-four hours after transfection, cell lysates were assayed for luciferase activity. Values are p21 cip1 promoterreporter luciferase activity normalized to protein levels and are presented relative to the activity of promoter-reporter with only an empty vector. B, Experiments were performed 3 times in triplicate.
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cantly more fibronectin, determined by both the absolute fibronectin-stained area and the percentage of the fibronectinstained area relative to the neointimal lesion ( Figure 6 ). Immunostaining for fibronectin in ApoE Ϫ/Ϫ and DKO mice demonstrated a trend to lower fibronectin deposition in DKO mice compared with ApoE Ϫ/Ϫ mice (supplemental Figure  III) . Because 12S-HETE induction of fibronectin has mediated monocyte adhesion, 30, 31 injured artery sections from BL-6, 12/15LO-tg, ApoE Ϫ/Ϫ , and DKO mice were stained with an anti-MAC-2 antibody (supplemental Figure IV) . Although there was increased MAC-2 staining in the mice on an ApoE Ϫ/Ϫ compared with a BL-6 background, there was no statistically significant differences in MAC-2 staining with increase or loss of 12/15LO expression (data not shown).
Discussion
In vivo studies 12, 17 have previously shown that 12/15LO expression is induced after vascular injury. Ribozymemediated or pharmacological inhibition studies 12, 13 have shown reduced NIF when injury-induced 12/15LO expression is blocked. Our data demonstrating reduced NIF in the DKO compared with the ApoE Ϫ/Ϫ mice provide further evidence that loss of 12/15LO attenuates the vascular response to injury. In addition to these loss-of-function studies, herein we extend the existing literature by providing the first data on the effect of increased baseline 12/15LO expression on NIF in response to injury. Relevance for determining the impact of baseline increase in 12/15LO on vascular lesion formation is provided by several studies demonstrating that conditions associated with accelerated vascular response to injury (eg, increased oxidative stress and type 2 diabetes) are associated with enhanced 12/15LO expression. 11,18 -21 12 /15LO has been implicated in mediating monocyte adhesion to endothelial cells 31, 32 and VSMCs. 33 In addition, 12/15LO is abundantly expressed in macrophages 19 and regulates processes in macrophages implicated in atherogenesis. 31, 34 Indeed, disruption of the 12/15LO gene diminished atherosclerosis in ApoE Ϫ/Ϫ mice, 35 and macrophage 12/15LO has been implicated in this effect. 36 Results of the present study demonstrate that in addition to reduced atherosclerosis, DKO mice have attenuated NIF in response to injury. Although loss of 12/15LO in macrophages may have contributed to the attenuated response to injury in DKO mice, our findings that cultured VSMCs from DKO mice have attenuated proliferation compared with ApoE Ϫ/Ϫ controls suggest that reduced VSMC proliferation may be an additional mechanism contributing to attenuated NIF in DKO mice.
To address the role of 12/15LO in mediating VSMC proliferation in vivo, we performed additional injury studies using gentle wire denudation of the carotid in a BL-6 mouse background. This model limits the effects of marked hyperlipidemia and macrophage infiltration on NIF. This model does not result in robust inflammatory lesions with macrophage infiltration, 37 such as that found in Western-fed ApoE Ϫ/Ϫ mice. 38 Indeed, in contrast to ApoE Ϫ/Ϫ mice, MAC-2 staining revealed no immunoreactivity in the BL-6 control and 12/ 15LO-tg mice 28 days after injury (supplemental Figure IV) . Consistent with previously published data 9,10 demonstrating enhanced proliferation in cultured BL-6 VSMCs with increased 12/15LO expression, results in vivo provide evidence that animals with increased baseline 12/15LO expression have increased neointimal size in response to injury. Although lesion size in this BL-6 model is small, results clearly demonstrate significant increases in Ki-67 immunoreactivity and cell content. These data provide the first in vivo evidence suggesting that enhanced neointimal cell proliferation may be a mechanism by which increased baseline 12/15LO promotes NIF.
Mechanisms by which 12/15LO enhances VSMC proliferation are poorly understood. Previous studies in cultured VSMCs provide evidence that a 12/15LO-induced increase in VSMC proliferation is mediated by the HLH factor, Id3. Overexpression of 12/15LO increased Id3 promoter activation, suggesting that 12/15LO regulates expression of the Id3 gene at the level of transcription. Id3 is a known growth factor-inducible gene that inhibits VSMC expression of the cyclin-dependent kinase inhibitor p21 cip1 , a key cell cycle factor that inhibits G 1 to S progression and VSMC proliferation. 22, 39 Id3 inhibits p21 cip1 expression via dimerization with basic HLH factors that activate p21 cip1 transcription. 40 To our knowledge, results of the present study are the first to identify ITF-2b as a factor that activates the p21 cip1 promoter in VSMCs and to determine that this activation is enhanced in the absence of Id3. Consistent with these findings, in 12/ 15LO-tg VSMCs, ITF-2b binding to the p21 cip1 promoter is significantly enhanced in the absence of Id3, suggesting a potential molecular mechanism by which Id3 may mediate the growth-promoting effects of 12/15LO. Increased Id3 protein expression in VSMCs with increased expression of 12/15LO and attenuated 12/15LO- induced VSMC proliferation in VSMCs from mice null for Id3 10 provide evidence that Id3 is a downstream regulator of 12/15LO-induced VSMC proliferation in culture. In vivo, Id3 expression is induced during vascular lesion formation in response to injury. 26, 27, 41 Herein, we provide evidence that elevated 12/15LO expression at baseline resulted in increased postinjury Id3 expression. Moreover, loss of Id3 attenuated the increased neointimal Ki-67positive staining in the injured 12/15LO-tg animals, providing evidence that Id3 is essential for 12/15LO-induced vascular wall proliferation.
In addition to VSMC proliferation, VSMC hypertrophy, migration, or matrix production may contribute as mechanisms by which increased 12/15LO expression promotes NIF. 12/15LO promotes VSMC migration, and 12/15LO products of arachidonic acid have hypertrophic effects and increase the expression of the fibronectin gene in VSMCs in culture. 5, 7, 8 Herein, results extend these in vitro data, demonstrating a significant increase in fibronectin deposition in the neointima in response to injury in the 12/15LO-tg mice compared with the BL-6 controls.
Interestingly, although loss of Id3 limits neointimal proliferation in response to injury in the 12/15LO-tg mouse on a BL-6 background, loss of Id3 in ApoE Ϫ/Ϫ mice resulted in an increase in atherosclerosis, 42 underscoring the important differences in atherosclerosis and restenosis models. The pathophysiological features of the response to percutaneous vascular interventions (restenosis) in humans and to endothelial denudation in animal models have distinct features from the pathophysiological features of atherogenesis. 43 Factors that may play a key role in regulating the response to mechanical injury in the vessel wall may have no or an opposite effect on atherogenesis. 44 A previously published study 37 has clearly demonstrated that the genetic determinants for injury-induced NIF and diet-induced atherosclerosis in inbred mice are distinct.
In summary, our in vivo study provides evidence that baseline elevated levels of 12/15LO, as seen in metabolic syndrome and diabetes, result in increased VSMC proliferation, fibronectin deposition, and NIF in response to injury. Moreover, the 12/15LO-induced proliferation is Id3 dependent, suggesting that 12/15LO and/or Id3 may be important targets for limiting restenosis. 
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